Designing the Furin-Cleavable Linker in Recombinant Immunotoxins Based on Pseudomonas Exotoxin A

Bioconjugate Chemistry

Volumn 26, Issue 6, 2015, Pages 1120-1128

  Weldon, John E ^a,b   Skarzynski, Martin ^b,c   Therres, Jamy A ^a,b   Ostovitz, Joshua R ^a,d   Zhou, Hong ^b   Kreitman, Robert J ^b   Pastan, Ira ^b  

^a TOWSON UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; BACTERIA; CELL CULTURE; DISEASES; RECOMBINANT PROTEINS;

'CURRENT; ANTIBODY-FRAGMENT; CATALYTIC DOMAINS; CELL KILLING; CLEAVAGE SITES; CLINICAL TRIAL; FUSION PROTEINS; IMMUNOTOXINS; PROTEIN TOXINS; PSEUDOMONAS EXOTOXIN A;

CYTOTOXICITY;

ADENOSINE TRIPHOSPHATE; FURIN; HYBRID PROTEIN; IMMUNOTOXIN; MESOTHELIN; MOXETUMOMAB PASUDOTOX; POLYPEPTIDE; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; RECOMBINANT IMMUNOTOXIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; EXOTOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER CELL LINE; CANCER IMMUNOTHERAPY; CELL VIABILITY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DRUG TARGETING; EC50; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; INTOXICATION; LEUKEMIA CELL; LUNG ADENOCARCINOMA; LYMPHOMA CELL LINE; MESOTHELIOMA; NONHUMAN; POINT MUTATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ENGINEERING; PSEUDOMONAS AERUGINOSA; WESTERN BLOTTING; AMINO ACID SEQUENCE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; LEUKEMIA; METABOLISM; TUMOR CELL LINE;

PSEUDOMONAS EXOTOXIN;

ADP RIBOSE TRANSFERASES; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CELL LINE, TUMOR; CELL SURVIVAL; EXOTOXINS; FURIN; HUMANS; IMMUNOTOXINS; LEUKEMIA; MODELS, MOLECULAR; RECOMBINANT FUSION PROTEINS; VIRULENCE FACTORS;

EID: 84934897412     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.5b00190     Document Type: Article

References (39)

1. Weldon, J. E. and Pastan, I. (2011) A guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer FEBS J. 278, 4683-4700
2. Kreitman, R. J. and Pastan, I. (2011) Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox Clin. Cancer Res. 17, 6398-6405
3. Decker, T., Oelsner, M., Kreitman, R. J., Salvatore, G., Wang, Q. C., Pastan, I., Peschel, C., and Licht, T. (2004) Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins Blood 103, 2718-2726
4. Alderson, R. F., Kreitman, R. J., Chen, T., Yeung, P., Herbst, R., Fox, J. A., and Pastan, I. (2009) CAT-8015: a second-generation Pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies Clin. Cancer Res. 15, 832-839
5. Kreitman, R. J., Tallman, M. S., Robak, T., Coutre, S., Wilson, W. H., Stetler- Stevenson, M., Fitzgerald, D. J., Lechleider, R., and Pastan, I. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia J. Clin. Oncol. 30, 1822-1828
6. Hassan, R., Bera, T., and Pastan, I. (2004) Mesothelin: a new target for immunotherapy Clin. Cancer Res. 10 (12 Pt 1) 3937-3942
7. Kreitman, R. J., Hassan, R., Fitzgerald, D. J., and Pastan, I. (2009) Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P Clin. Cancer Res. 15, 5274-5279
8. Hassan, R., Bullock, S., Premkumar, A., Kreitman, R. J., Kindler, H., Willingham, M. C., and Pastan, I. (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers Clin. Cancer Res. 13, 5144-5149
9. Hassan, R., Miller, A. C., Sharon, E., Thomas, A., Reynolds, J. C., Ling, A., Kreitman, R. J., Miettinen, M. M., Steinberg, S. M., and Fowler, D. H. 2013, Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression Sci. Transl. Med. 5, 208ra147
10. Chowdhury, P. S. and Pastan, I. (1999) Improving antibody affinity by mimicking somatic hypermutation in vitro Nat. Biotechnol. 17, 568-572
11. Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J., and Pastan, I. (2002) Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display Clin. Cancer Res. 8, 995-1002
12. Seetharam, S., Chaudhary, V. K., FitzGerald, D., and Pastan, I. (1991) Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL J. Biol. Chem. 266, 17376-17381
13. Weldon, J. E., Xiang, L., Chertov, O., Margulies, I., Kreitman, R. J., FitzGerald, D. J., and Pastan, I. (2009) A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity Blood 113, 3792-3800
14. Liu, W., Onda, M., Kim, C., Xiang, L., Weldon, J. E., Lee, B., and Pastan, I. (2012) A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity Protein Eng. Des. Sel. 25, 1-6
15. v fragment Proc. Natl. Acad. Sci. U.S.A. 90, 7538-7542
16. v Protein Eng. 7, 697-704
17. Onda, M., Beers, R., Xiang, L., Lee, B., Weldon, J. E., Kreitman, R. J., and Pastan, I. (2011) Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes Proc. Natl. Acad. Sci. U.S.A. 108, 5742-5747
18. Liu, W., Onda, M., Lee, B., Kreitman, R. J., Hassan, R., Xiang, L., and Pastan, I. (2012) Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes Proc. Natl. Acad. Sci. U.S.A. 109, 11782-11787
19. Mazor, R., Vassall, A. N., Eberle, J. A., Beers, R., Weldon, J. E., Venzon, D. J., Tsang, K. Y., Benhar, I., and Pastan, I. (2012) Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A Proc. Natl. Acad. Sci. U.S.A. 109, E3597-E3603
20. Mazor, R., Eberle, J. A., Hu, X., Vassall, A. N., Onda, M., Beers, R., Lee, E. C., Kreitman, R. J., Lee, B., and Baker, D. 2014, Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes Proc. Natl. Acad. Sci. U.S.A. 111, 8571-8576
21. Thomas, G. (2002) Furin at the cutting edge: from protein traffic to embryogenesis and disease Nat. Rev. Mol. Cell Biol. 3, 753-766
22. Ogata, M., Chaudhary, V. K., Pastan, I., and FitzGerald, D. J. (1990) Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol J. Biol. Chem. 265, 20678-20685
23. McKee, M. L. and FitzGerald, D. J. (1999) Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story Biochemistry 38, 16507-16513
24. Weldon, J. E., Xiang, L., Zhang, J., Beers, R., Walker, D. A., Onda, M., Hassan, R., and Pastan, I. (2013) A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity Mol. Cancer Ther. 12, 48-57
25. Duckert, P., Brunak, S., and Blom, N. (2004) Prediction of proprotein convertase cleavage sites Protein Eng. Des. Sel. 17, 107-112
26. Remacle, A. G., Shiryaev, S. A., Oh, E. S., Cieplak, P., Srinivasan, A., Wei, G., Liddington, R. C., Ratnikov, B. I., Parent, A., and Desjardins, R. 2008, Substrate cleavage analysis of furin and related proprotein convertases. A comparative study J. Biol. Chem. 283, 20897-20906
27. Izidoro, M. A., Gouvea, I. E., Santos, J. A., Assis, D. M., Oliveira, V., Judice, W. A., Juliano, M. A., Lindberg, I., and Juliano, L. (2009) A study of human furin specificity using synthetic peptides derived from natural substrates, and effects of potassium ions Arch. Biochem. Biophys. 487, 105-114
28. Tian, S. (2009) A 20 residues motif delineates the furin cleavage site and its physical properties may influence viral fusion Biochem. Insights 2, 9-20
29. Tian, S., Huang, Q., Fang, Y., and Wu, J. (2011) FurinDB: A database of 20-residue Furin cleavage site motifs, substrates and their associated drugs Int. J. Mol. Sci. 12, 1060-1065
30. Moehring, J. M., Inocencio, N. M., Robertson, B. J., and Moehring, T. J. (1993) Expression of mouse furin in a Chinese hamster cell resistant to Pseudomonas exotoxin A and viruses complements the genetic lesion J. Biol. Chem. 268, 2590-2594
31. Chiron, M. F., Fryling, C. M., and FitzGerald, D. (1997) Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins J. Biol. Chem. 272, 31707-31711
32. Becker, G. L., Lu, Y., Hardes, K., Strehlow, B., Levesque, C., Lindberg, I., Sandvig, K., Bakowsky, U., Day, R., and Garten, W. 2012, Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases J. Biol. Chem. 287, 21992-22003
33. Gawlik, K., Remacle, A. G., Shiryaev, S. A., Golubkov, V. S., Ouyang, M., Wang, Y., and Strongin, A. Y. (2010) A femtomol range FRET biosensor reports exceedingly low levels of cell surface furin: implications for the processing of anthrax protective antigen PLoS One 5, e11305
34. Tortorella, L. L., Pipalia, N. H., Mukherjee, S., Pastan, I., Fitzgerald, D., and Maxfield, F. R. (2012) Efficiency of immunotoxin cytotoxicity is modulated by the intracellular itinerary PLoS One 7, e47320
35. OReilly, M. K., Tian, H., and Paulson, J. C. (2011) CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells J. Immunol. 186, 1554-1563
36. Fujita, M. and Kinoshita, T. (2012) GPI-anchor remodeling: potential functions of GPI-anchors in intracellular trafficking and membrane dynamics Biochim. Biophys. Acta 1821, 1050-1058
37. Pastan, I., Beers, R., and Bera, T. K. (2004) Recombinant immunotoxins in the treatment of cancer Methods Mol. Biol. 248, 503-518
38. Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012) NIH Image to ImageJ: 25 years of image analysis Nat. Methods 9, 671-675
39. Bera, T. K., Onda, M., Kreitman, R. J., and Pastan, I. (2014) An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies Leuk. Res. 38, 1224-1229